All Episodes

Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings

Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC

From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM?

Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

The ON Switch: Overcoming KRAS Resistance Using Next-Generation Targeted Inhibitors in Advanced NSCLC

The Next Wave of CAR T Innovation for RRMM: Insights Into Emerging GPRC5D-Directed CAR T-Cell Therapies

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma

Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer

Survivorship Strategies for Patients on First-Line HER2+ mBC Maintenance Therapies: Practical Guidance on Monitoring and AE Management

Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change?

HER2 in Focus: Guiding Bladder Cancer Treatment Personalization in the Era of Antibody-Drug Conjugates

Facing Therapeutic Resistance to Maintenance Therapy: The Need for Novel Strategies in HER2+ mBC

RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC

Getting Practical About Optimizing Management of Stage II and III NSCLC: Expert Guidance to Elevate Care

Advancing Care in Unresectable Stage III NSCLC: Consolidation Immunotherapy and Beyond

Ticiana Leal, MD - Translating Trials to Treatment: Practical Strategies for Immunotherapy Integration in Limited-Stage and Extensive-Stage SCLC

Carolyn Owen, MD, MDres(UK), FRCPC - Innovations in Relapsed/Refractory CLL/SLL Therapy: Integrating Non-Covalent BTK Inhibitors for Improved Outcomes

Prof. Solange Peters, MD, PhD / Alfredo Addeo, MD - Patient-Centered Strategies in Early-Stage NSCLC: Navigating the Treatment Journey Together

Peter R. Galle, MD, PhD - Expanding Options, Elevating Outcomes: The Role of First-Line Combination Therapy for Unresectable HCC

Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies

Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy

Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC

Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors

Komal Jhaveri, MD, FACP, FASCO - From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer

Arielle Elkrief, MD / Normand Canty - Cases in Metastatic NSCLC: Optimizing Long-term Outcomes With Frontline Immunotherapy-Based Regimens

Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success

Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care

Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL

Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Optimizing Survivorship Across the Patient Journey, Including Lines of Therapy

Aditya Bardia, MD / Giuseppe Curigliano, MD, PhD - Sequencing in the Real World With Complex Patient Types, Including Underrepresented Populations

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC

Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap

Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes

Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer

Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk

Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma

John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC

Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer